Back to today’s briefing

Story perspectives

Unlocking Cancer Treatment: Glycosylation Biomarkers for RCC

1/23/2025

36 7

Summary

Story summary

David A. Braun, MD, PhD, from Yale Cancer Center, is urging a deeper investigation into protein glycosylation as a potential biomarker for renal cell carcinoma (RCC). While genomics has made strides, the impact of glycosylation on cancer progression and immune response is still largely overlooked. Identifying key glycopeptides could revolutionize immunotherapy and significantly boost treatment success.

1 of 1

Story summary

David A. Braun, MD, PhD, from Yale Cancer Center, is urging a deeper investigation into protein glycosylation as a potential biomarker for renal cell carcinoma (RCC). While genomics has made strides, the impact of glycosylation on cancer progression and immune response is still largely overlooked. Identifying key glycopeptides could revolutionize immunotherapy and significantly boost treatment success.